Response to 'Correspondence on 'Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort' by Ruyssen-Witrand et al

Summary: During the COVID-19 pandemic, there was a significant increase in remote assessments, with a slight increase in drug non-compliance among axSpA patients. However, disease flares remained stable overall in patients with axSpA, RA, and PsA.